GlassScriptPhysician profile
Padmini U Moffett
NPI 1568582930
$3,969.15
in general payments reported to CMS, 2019-2025
39 companies · $860 in 2025
The $860 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $846 · 2020: $409 · 2021: $260 · 2022: $56.07 · 2023: $689 · 2024: $850 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,398.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $433.81 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $419.30 | 2019-2025 | |
| Daiichi Sankyo INC. | $314.26 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Novartis Pharmaceuticals Corporation | $310.77 | 2019-2025 | |
| Amgen INC. | $291.15 | 2019-2022 | |
| Eisai INC. | $233.83 | 2019-2025 | |
| Incyte Corporation | $222.36 | 2019-2024 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $150.36 | 2019-2025 | Opdivo, Opdualag |
| Genzyme Corporation | $139.05 | 2019-2025 | |
| Janssen Biotech, INC. | $101.77 | 2019-2025 | Tecvayli |
| Rigel Pharmaceuticals, INC. | $99.14 | 2019-2023 | Rezlidhia, Tavalisse |
| Seagen INC. | $98.66 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $98.34 | 2019-2025 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $89.80 | 2019-2024 | |
| Genentech USA, INC. | $84.32 | 2019-2025 | Itovebi |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Padmini Moffett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.